- In January 2024 – Labcorp has launched a new test designed for the risk assessment and prognosis of severe preeclampsia. This test will allow healthcare providers to better assess a pregnant woman’s risk of developing severe preeclampsia, a potentially life-threatening condition. By using a combination of advanced biomarkers, the test offers more accurate predictions, enabling earlier intervention and improved management of the condition. This launch aims to enhance maternal health outcomes by providing more precise, timely data, reducing complications for both mothers and babies, and allowing for personalized care strategies in managing preeclampsia
- In January 2024, Mayo Clinic Laboratories has released a new first-to-market pregnancy risk assessment test in the U.S. The test is designed to evaluate the risk of preeclampsia, a serious pregnancy complication. By analyzing biomarkers associated with preeclampsia, this test provides healthcare providers with a more accurate understanding of a patient's risk level early in the pregnancy. This breakthrough enables better decision-making and the ability to take preventive measures, ultimately improving maternal and fetal outcomes by facilitating earlier interventions and more personalized care
- In July 2023, The U.S. Food and Drug Administration (FDA) approved a new blood test for diagnosing preeclampsia. This test provides healthcare professionals with a reliable tool to detect preeclampsia in pregnant women earlier in their pregnancies. By measuring specific biomarkers, the test helps assess the risk of developing this serious condition, which can lead to complications for both the mother and baby. The approval of this test allows for more timely intervention, improving outcomes by enabling early management and treatment of preeclampsia, ultimately enhancing the safety of both mothers and infants
